Lercanidipina Mylan Italia (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels on vascular smooth‑muscle cells. This inhibition prevents calcium entry, causing the muscles to relax, which dilates arteries and reduces peripheral resistance. The resulting vasodilation lowers arterial pressure without markedly affecting heart rate.

The appropriate dose of lercanidipine is determined individually by a qualified prescriber based on the patient’s blood‑pressure profile, age, renal and hepatic function, and concomitant medications. Patients should follow the exact dosing instructions provided by their healthcare professional.

Safety data for lercanidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and the necessary import documentation.

Both lercanidipine and amlodipine belong to the dihydropyridine class of calcium channel blockers and lower blood pressure by vasodilation. Lercanidipine has a longer half‑life and may be associated with a lower incidence of peripheral edema, while amlodipine is more widely studied and available in many fixed‑dose combinations.

Lercanidipina Mylan Italia tablets should be stored at ambient temperature, below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and keep out of reach of children.

Lercanidipine is taken orally, usually once daily. It can be swallowed with or without food; however, consistent intake with respect to meals helps maintain stable plasma levels. Patients should not crush or chew the tablets.

Serious adverse events, though rare, include severe hypotension, angioedema, myocardial infarction, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience sudden dizziness, swelling of the face or throat, chest pain, or signs of liver dysfunction.

Lercanidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation, in those with severe hypotension, cardiogenic shock, or unstable angina. Caution is also advised for patients with significant hepatic impairment.